Vertex Pharmaceuticals Share-Based Payment Tax Withholding Decrease increased by 1442.4% to $91.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.7%, from $83.70M to $91.00M.
Provides insight into the tax-related cash impact of equity compensation programs on the company's balance sheet.
This represents the cash value or reduction in equity associated with the company settling tax withholding obligations f...
Commonly reported in the Statement of Changes in Equity or Cash Flow Statement under financing activities.
is_anet_share_based_payment_tax_withholding_decrease| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $56.53M | $56.53M | $56.53M | $56.53M | $80.50M | $83.70M | $5.90M | $91.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +42.4% | +4.0% | -93.0% | >999% |
| YoY Change | — | — | — | — | +42.4% | +48.1% | -92.7% | +8.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.